There are no well-defined studies of chronic kidney disease (CKD) among long-term survivors after hematopoietic SCT. A retrospective longitudinal study was conducted to characterize CKD in 77 subjects that had undergone myeloablative allogeneic SCT, all of whom had their serum creatinine (Cr) levels followed-up during the 10-year period after SCT. Their mean (range) survival time was 14.4 (10.5-20.2) years. CKD was defined as a persistent decrease in the Cr-based estimated glomerular filtration rate to below 60 mL/min/1.73 m 2 . Acute kidney injury (AKI) was defined as an increase in Cr within the first 100 days after SCT, and its severity was classified into three stages according to the AKIN criteria. Kaplan-Meier and Cox proportional hazards regression analyses evaluated the association between AKI and the incidence of CKD. The cumulative incidence of CKD increased over time and reached 34% at 10 years. After adjusting for known risks for post-SCT CKD, each AKIN stage was strongly associated with the incidence of CKD. The incidence of CKD probably increases over time among subjects who are alive at 410 years after SCT. This study places a new emphasis on AKI as an important risk factor for CKD in post-SCT subjects.
INTRODUCTION
Chronic kidney disease (CKD) has emerged as a significant cause of morbidity and mortality among survivors of hematopoietic SCT. In the general population, CKD is increasingly recognized as a global public health problem. The outcomes of CKD include not only progression to ESRD (end-stage renal disease), but also increased risks of other chronic diseases such as CVD (cardiovascular disease), infections and cancer. [1] [2] [3] Accordingly, post-SCT survivors who develop CKD might be at greater risk of death, CVD events and hospitalization. 4 The prevention and appropriate treatment of CKD in such patients is an important issue that needs to be addressed by nephrologists and transplant physicians.
A study of 100 000 survivors of SCT who had received their graft at least 5 years ago showed that the overall burden of CKD in SCT represents a significant public health problem in the United States. 5 However, the lack of a consistent definition of post-SCT CKD, including the degree of renal function, the timing of its occurrence, SCT types and the follow-up period, has made it difficult to draw comparisons among previous studies and identify risk factors for post-SCT CKD. The detection, evaluation and management of CKD according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/ DOQI) guidelines has generally been accepted, 6 and thus, facilitates comparisons between studies on CKD after SCT. Therefore, we examined whether the incidence and prevalence of CKD increase over time after SCT, according to the K/DOQI definition of CKD, in subjects that had survived without relapsing for 410 years after SCT. In addition, we attempted to elucidate which risk factor most contributes to the occurrence of CKD in these subjects.
MATERIALS AND METHODS

Study cohort and design
A retrospective longitudinal study was performed to characterize CKD in patients who had survived without relapsing for 410 years after receiving myeloablative allogeneic SCT between January 1990 and December 1999. A total of 217 patients received their first myeloablative allogeneic SCT in our hospital between January 1990 and December 1999. One hundred and nine patients (50.2%) survived for 410 years, 76 patients (35.0%) died within 10 years and 32 patients (14.7%) moved to local hospitals without our follow-up. This study included subjects for whom consecutive serum creatinine (Cr) measurements had been taken during the 10-year period after SCT, including measurements for the following eight time points: pretransplant and post-SCT day 0, day 100, 0.5 year, 1 year, 2 years, 5 years and 10 years. Among 109 survivors over 10 years, eight patients relapsed and received the second myeloabrative allogeneic SCT, and complete Cr data sets were not collected from another 24 patients, as they moved to local hospitals in the middle of the follow-up. Therefore, they were excluded from the study. There were no significant differences in clinical and demographic data at baseline between long-term survivors who were included in the study and those who were not. Subjects that displayed CKD in the pre-transplant period were excluded, too. A total of 77 subjects (44 men and 33 women), who were followed-up for over 10 years and had no missing data, were included. The 77 subjects' mean age at SCT was 32 (range, 15-57), and their mean survival time was 14.4 years (range, 10.5-20.2) at the time of analysis. The underlying lymphohematological diseases were chronic myeloid leukemia (n ¼ 34), acute myelocytic leukemia (n ¼ 15), acute lymphocytic leukemia (n ¼ 12), myelodysplastic syndrome (n ¼ 6), severe aplastic anemia (n ¼ 6), non-Hodgkin's lymphoma (n ¼ 3) and myelofibrosis (n ¼ 1). When a Cr value for an index time point was missing, the value for the most recent previous time point was used.
The Cr values and demographic/laboratory data for each person were collected from their medical records and analyzed in February 2010. The patients gave their informed consent and were treated according to the protocols approved by the institutional ethics committee. 7 When a decrease in eGFR developed after at least 6 months after SCT and was sustained until the last follow-up examination of the 10-year study period, the patient was defined as having CKD. Acute kidney injuries (AKI) occurring within the first 100 days were staged according to the severity staging criteria advocated by the acute kidney injury network (AKIN) 8 : stage 1: increase in the serum Cr level of X0.3 mg/ dL or a 1.5-to 1.9-fold increase from the baseline; stage 2:X2.0-to 2.9-fold increase in the serum Cr level from the baseline; stage 3: increase in the serum Cr level of X3.0-fold from the baseline or a serum Cr level ofX4.0 mg/dL with an acute increase of at least 0.5 mg/dL. For convenience, non-AKI is denoted by the term 'stage 0' in this article. The urine output criteria included in the AKIN criteria were not used, as we were unable to obtain accurate records of urine output for all patients. The serum Cr concentration was measured by an enzymatic method using an isotope-dilution mass spectrometry-traceable calibrator (N-assay L Creatinine Kit, Nittoubo Medical Co., Tokyo, Japan).
Preconditioning therapy for the myeloablative procedure
The preconditioning therapy employed depended on the patient's primary disease and the type of transplant that they received. Patients with lymphoid malignancy were conditioned using a TBI-containing regimen (12 Gy in six fractions over 3 consecutive days; at least 6 h between the two daily fractions) that included cytarabine (2 g/m 2 via an intravenous drip for 4 days) and CY (60 mg/kg via an intravenous drip for 2 days). Patients with myeloid malignancies were conditioned using a non-TBI-containing regimen including BU (1 mg/kg orally every 6 h for 4 days) and CY (60 mg/kg via an intravenous drip for 2 days). TLI involving the delivery of 7 Gy in two fractions was included in the BU/CY regimens in cases of mismatched or unrelated transplantation. Patients with severe aplastic anemia were also conditioned using a TLI-containing regimen. After March 1999, selective kidney-shielding blocks were used during TBI, which reduced the renal dose to 10 Gy. 9 
Prophylaxis treatment
The GVHD prophylaxis regimen comprised a short course of methotrexate and cyclosporine or tacrolimus. Tacrolimus was used in cases involving unrelated or mismatched transplantation. Acute and chronic GVHD were diagnosed and graded according to previously established criteria. 10, 11 Tosufloxacin and fluconazol were orally administered for 14 days before SCT. Trimethoprim-sulfamethoxazole was also used to prevent pneumocystis pneumonia. CMV infection was treated with ganciclovir twice daily until a negative CMV test result was obtained.
Statistical analysis
Data are shown as the mean ± s.d. unless otherwise stated. Comparisons between the two groups were performed using the Mann-Whitney U-test for continuous variables and the w 2 test or Fisher's exact test (where appropriate) for categorical variables. Cumulative curves of CKD incidence were prepared using the Kaplan-Meier method, and the log-rank test was used to analyze the differences between the curves. A multivariate Cox proportional hazards regression model, which was adjusted for known CKD risk factors including sex, age at transplantation, exposure to irradiation as part of the conditioning regimen, and a history of chronic GVHD, was constructed to determine the association between AKI and the time to CKD occurrence within the initial 10 years after SCT. 12 Adjusted HRs (hazard ratios) and 95% confidence intervals were calculated for each risk factor. JMP version 9 (SAS Institute Japan, Cary, CA, USA) was used for all the statistical analyses. Values of Po0.05 were considered statistically significant.
RESULTS
Incidence of CKD in each year after SCT When we reviewed the proportions of subjects that developed CKD in each post-SCT year, we found that the patients were more likely to develop CKD in the first year after SCT (10.3%) than in the following years. The incidence of CKD was 3.9% in the second year, 3.9% in the third year, 2.6% in the fourth year, 1.3% in the fifth year, 2.6% in the sixth year, 3.9% in the seventh year, 2.6% in the eighth year, 0% in the ninth year and 2.6% in the 10th year. Accordingly, the cumulative incidence of CKD increased over time and reached 34% (26 of 77 subjects) at 10 years after SCT, as shown in Figure 1 .
Comparison between subjects who did and did not develop CKD during the follow-up period Table 1 shows a comparison of the patients who did and did not develop CKD. Of the 77 subjects, 26 (34%) developed CKD during the study period. The bone marrow was the stem cell source for all subjects. Fifty-eight subjects (75%) received stem cells from unrelated donors, and 7 (9.1%) received them from single HLAmismatched donors. Conditioning regimens involving irradiation, including TBI (17 patients) and TLI (17 patients), were performed in 34 patients (44.8%). Of the TBI recipients, 16 (94%) underwent procedures that did not involve kidney-shielding blocks, as their transplants were performed before March 1999. None of the subjects without AKI developed CKD.
Association between AKI and CKD Figure 2 demonstrates the graded relationship between the severity of AKI and time to the occurrence of CKD. It also shows that none of the subjects without AKI (stage 0) developed CKD, and that the risk of CKD did not differ significantly between the AKIN stages at 10 years after SCT. In addition, multivariate Cox analysis showed that when stage 0 AKI was set as the reference the development of AKI, regardless of its severity, was strongly associated with CKD occurrence. The adjusted HR appeared to increase with increasing AKI stage, but there were no significant differences among them. Otherwise, age at transplant and exposure to irradiation were significantly related to CKD, but a history of chronic GVHD was not, as shown in Table 2 .
Cumulative number of CKD patients
Number of non-CKD patients in each year after SCT 
n=77 n=69 n=66 n=63 n=61 n=60 n=58 n=55 n=53 n=53 Figure 1 . Cumulative incidence of CKD during the 10 years after SCT. The Kaplan-Meier curve shows that the cumulative incidence of CKD increased with time and reached 34% at 10 years after the transplant.
DISCUSSION
This retrospective longitudinal study characterized CKD among patients that had survived for a long period after myeloablative allogeneic SCT. The patients were more likely to develop CKD in the first year than in the following years, and the proportion of patients that developed CKD increased with time after SCT, resulting in a cumulative incidence of 34% at 10 years. In addition, patients who experienced any AKI in the peri-SCT period were at very high risk of developing CKD.
This study analyzed the no-missing consecutive Cr data of subjects that had survived for at least 10 years after SCT, which probably contributed to the fact that this study displayed the highest incidence of CKD (34% at 10 years) among studies of this type. Choi et al. 13 undertook a retrospective follow-up study (median follow-up period, 7.1 years; range, 1-24.3 years) of 1190 patients who underwent SCT including autologous and allogeneic SCT at the age of X18 years (median, 35; range, 18.1-68.6 years) and survived for at least 1 year. They showed that the cumulative incidence of CKD was 4.2% at 5 years in HLA-matched related SCT recipients and 10% at 5 years in HLA-matched unrelated SCT recipients. However, it was unclear whether this study included patients that had undergone non-myeloablative or reducedintensity conditioning SCT. Kersting et al.
14 performed a retrospective study of 266 adults (mean age, 38.3; range, 17-56 years) who had received myeloablative allogeneic SCT and been followed-up for a mean of 5.1 years (range, 0.6-13.1 years). They showed that CKD had developed in 61 (23%) patients at a mean of 2.6 years, with a cumulative incidence rate of 27% at 10 years. Both of the above studies included some data for subjects with a short follow-up period of o2 years or 1 year, respectively, although the definition of CKD in both studies was similar to the K/DOQI definition. In addition, both studies demonstrated an increase in the cumulative incidence of CKD over time, as was seen in our study. These findings suggest that cohorts with longer follow-up periods are likely to display a higher incidence of CKD.
Our study suggested that patients are at greater risk of CKD in the first year after SCT than in the following years. We were unable 112 (31) 115 (31) 107 (29) Donor source Unrelated, number (%) 58 (75) 11 (22) 8 (31) HLA mismatch Yes, number (%) 7 (9.1) 4 (7.8) 3 (11)
Irradiation exposure: Yes, number (%) TBI without kidneyshielding blocks
16 (21) 7 (14) 9 (35) TBI with kidney-shielding blocks
TLI 17 (22) 11 (22) 6 (23) Acute GVHDXgrade 2 Yes, number (%) 23 (30) 14 (27) Table 1 . There were no statistically significant differences in the HR among AKI stages 1, 2 and 3.
CKD in long-term survivors after SCT T Shimoi et al to determine the reasons for this, but AKI occurring in the peri-SCT period might contribute to the increased occurrence of CKD in the first year after SCT, and the high proportion of calcineurin inhibitor recipients during the initial year following SCT might also be involved. 12, 15 Several risk factors have been suggested to be associated with SCT-CKD. We found that none of the non-AKI subjects suffered CKD during the 10-year follow-up period, and that the presence of any AKI, regardless of its severity, was significantly associated with time to the occurrence of CKD. In general, the presence of a minor AKI is known to be a risk for future CKD, which is the primary reason why the conventional paradigm of acute kidney failure had to be changed and new criteria, such as the RIFLE and the AKIN criteria, had to be created. 8, [16] [17] [18] [19] However, no link between CKD and AKI severity has been confirmed in SCT patients with a long survival period. The current study was the first to clarify the involvement of each AKIN stage, although an association between unclassified overall AKI and CKD has been suggested in previous papers. [20] [21] [22] Numerous studies have reported that irradiationbased procedures affect the risk of CKD, 9,23-27 and our study confirmed the significant impact of irradiation. In addition, some papers have suggested that the long-term use of calcineurin inhibitors, probably due to refractory chronic GVHD, 12, 28 is another risk factor for CKD, but our study did not address this issue, as we were unable to collect accurate records regarding the usage of calcineurin inhibitors for all subjects.
Due to its retrospective observational nature, this study had several limitations. First, we could not adequately examine the presence or clinical courses of comorbidities associated with the occurrence of CKD, including hypertension and diabetes before the development of CKD. Second, the total dose and duration of calcineurin inhibitor treatment and the usage of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers were not examined, although they are considered to affect the risk and course of SCT-related nephropathy. 29, 30 Third, GFR was not estimated with the Modification of Diet in Renal Disease (MDRD) study equation. GFR is usually estimated from the patient's serum creatinine level, age, sex and ethnicity (African American vs Caucasians) using the MDRD study equation. However, there has always been concern about the MDRD study equation's ethnicity coefficient because it does not take account of non-Caucasian non-African American ethnic groups. The Japanese Society of Nephrology has confirmed that the MDRD study equation is less accurate for Asians and produces a bias towards an estimated GFR of o60 mL/min/1.73 m 2 in this group. 7, 31, 32 Thus, our results might be more accurate than those obtained with the MDRD study equation, but are unlikely to be generalizable to other races, as we used a Japanese specific equation. Finally, there might have been some inclusion bias, as the study subjects periodically visited the hospital over the 10-year study period due to unspecified complaints.
In conclusion, the improvement of SCT-related medicines has contributed to the increased number of long-term survivors after SCT. Among them, patients that develop CKD may be at a greater risk of chronic illnesses including ESRD and CVD. Greater recognition of post-SCT CKD should be encouraged among health professionals, which would contribute to lowering the risk of progression to ESRD and preventing other chronic complications in subjects that have undergone successful SCT.
